Best Peptides for Cartilage & Meniscus Repair (2026)

Pentosan polysulfate is a semi-synthetic sulfated xylan polysaccharide (a heparinoid / GAG-mimetic) built from a beechwood-derived carbohydrate backbone with no amino acids or peptide bonds — so despite being constantly grouped with BPC-157 and TB-500 in joint-peptide discussions, it is not a peptide at all. It earns the top slot precisely because it is the only molecule in this group with controlled human data touching cartilage outcomes. A double-blind, placebo-controlled pilot RCT (Ghosh 2005, n=114; NaPPS 3 mg/kg IM weekly for four weeks) found significant benefits over placebo for joint stiffness, pain at rest, and patient global assessment, with benefit persisting about 20 weeks after a four-week course. An open-label trial (Kumagai 2010, n=20 women) reported a significant roughly 19-22% fall in serum C2C, a type-II-collagen cartilage-degradation biomarker, alongside large reductions in stair and walking pain. Crucially, neither trial used MRI or radiographic endpoints, so human cartilage preservation — let alone regrowth — remains unproven, making the structural claim only Grade C even though the OA-symptom evidence is Grade B. Mechanistically it stimulates chondrocyte proteoglycan synthesis even in the presence of IL-1b, improves subchondral blood flow, and inhibits cartilage-degrading enzymes. Confirmatory Phase 3 subcutaneous trials are active in 2025-2026. It has no human meniscus-repair data — it is a diffuse osteoarthritis drug candidate, not a focal-tear fix.

Best for

Readers researching the only molecule in the joint-peptide conversation with controlled human data — understanding it is a polysaccharide, its benefit is for OA pain/biomarkers not proven regrowth, and it has no meniscus data

Pricing

Oral Elmiron FDA-approved for bladder only; injectable PPS not FDA-approved in the US

Source: Ghosh et al., Curr Ther Res 2005 — NaPPS knee OA pilot RCT (PMID 24678076)

AOD-9604 is a 16-amino-acid synthetic fragment of the C-terminal lipolytic tail of human growth hormone (Tyr-hGH 177-191), originally an anti-obesity candidate, re-coded LAT8881 for a cartilage and osteoarthritis program. An independent 2025 orthopaedics review singles it out as receiving the most specific cartilage evidence of the candidate peptides — but that evidence is a single animal study: a collagenase-induced knee-OA model in 32 New Zealand white rabbits in which weekly intra-articular AOD-9604 (0.25 mg), especially combined with hyaluronic acid (6 mg), enhanced cartilage regeneration and reduced histopathologic degeneration versus saline. It is proposed to act as a lanthionine synthetase C-like protein (LANCL) activator, a mechanism explored specifically for cartilage — a genuinely distinct and appealing rationale, but one that remains entirely preclinical. The decisive weakness is the human record: AOD-9604 is the rare peptide that completed six human RCTs (n=893), but all were for obesity and all established only safety, with no effect on serum IGF-1 and no orthopaedic RCTs of any kind. Any human cartilage claim is therefore extrapolation from one rabbit study — promising mechanistically, unproven clinically. There is no meniscus data of any kind. Intra-articular human safety is entirely uncharacterized, and it is WADA-prohibited at all times as a growth-hormone fragment.

Best for

Readers comparing the most cartilage-specific peptide mechanism against the honest limit of its evidence — one rabbit study, no human joint trial

Pricing

Not FDA-approved; sold as research chemical / via compounding gray zone

Source: Kwon & Park, Ann Clin Lab Sci 2015 — IA AOD-9604 ± HA, rabbit OA (PMID 26275694)

BPC-157 is a synthetic stable gastric pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric protein, and it has the broadest preclinical case in this class — though heavily single-lab-dominated. In a rat knee-osteoarthritis model created by transecting the ACL and MCL plus a medial meniscectomy, control animals developed near-total cartilage and proximal-tibia destruction by eight weeks, whereas intra-articular BPC-157 rats had articular surfaces similar to non-operated animals at four weeks and only minor cartilage lesions at eight weeks, with X-ray-confirmed preserved bone and restored walking, leg-pressure, and knee-mobility function. Critically, the meniscectomy in that model is the injury-induction method, not a demonstration of meniscus repair. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical and only 1 clinical. The human evidence is essentially one joint-relevant report: a retrospective, uncontrolled case series (~17 patients) of intra-articular BPC-157 for assorted knee pain, with most reporting relief lasting over six months — but no control group, no validated outcomes, no imaging, and a single author and journal. All published human BPC-157 reports share that lead author, so they cannot be treated as independent confirmation. Its mechanism upregulates VEGFR2 and modulates nitric oxide to promote angiogenesis — plausibly useful at the vascular red-zone meniscus rim or subchondral interface, but of little use in avascular hyaline cartilage or the inner meniscus, the very targets buyers care about. No isolated human meniscus-repair data exist, and no controlled human cartilage trial exists.

Best for

Readers researching the peptide with the broadest preclinical OA record — understanding the human evidence is a single uncontrolled series and the mechanism is weakest in avascular cartilage

Pricing

Not FDA-approved; sold as research chemical / via compounding gray zone

Source: Sikiric et al., FASEB J 2014 — IA BPC-157 in rat knee OA (ACL/MCL + meniscectomy)

GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper (1:1), a human matrix-remodeling tripeptide isolated by Pickart in 1973. It has genuinely strong human evidence — but for skin and wound healing, not joints. Its cartilage case is entirely in-vitro and mechanistic: at nanomolar (1-10 nM) concentrations it stimulates synthesis of collagen, dermatan and chondroitin sulfate, and the proteoglycan decorin; in stressed chondrocyte culture it raised glycosaminoglycan synthesis and reduced IL-1b-induced cell death; and it downregulates the matrix-degrading enzymes MMP-1 (about 37%) and MMP-3 (about 52%) along with inflammatory cytokine signaling relevant to OA pathology. That is genuinely attractive biology — it targets both sides of the cartilage balance, building matrix while suppressing the enzymes that dissolve it. But an independent orthopaedics review classifies its joint use as preclinical or early studies only, citing soft-tissue regeneration and scar modulation rather than cartilage outcomes, and no human knee, cartilage, or meniscus clinical trial supports efficacy. A practical limitation compounds the evidence gap: a peptide that boosts glycosaminoglycan in a dish must still reach cartilage at therapeutic concentration through the synovium, and cartilage remodeling is mechanically driven — so any real-world benefit would be contingent on active loading and rehab, not passive dosing. Injectable joint safety is not established in controlled human studies, and injectable GHK-Cu was swept into the FDA compounding review.

Best for

Readers who have seen GHK-Cu marketed for knees and want an honest accounting of why its joint case is in-vitro only despite strong skin data

Pricing

Topical products exist; injectable/intra-articular not FDA-approved (compounding gray zone)

Source: Pickart & Margolina, Int J Mol Sci 2018;19(7):1987 — GHK-Cu regenerative actions

We group these two together as also-rans because both are aggressively marketed in the joint space yet have the thinnest cartilage and meniscus evidence of anything here. TB-500 is a synthetic fragment of thymosin β-4 (Tβ4), a naturally occurring actin-regulating protein; a 2026 scoping review mapping Tβ4 and TB-500 across tissue repair found the literature weighted toward in-vitro and animal designs, with most studies evaluating Tβ4 rather than TB-500 itself, and cartilage a comparatively sparse category. Human Tβ4 data exist in eye and skin conditions, not joints, so there is no human cartilage or meniscus evidence for it at all — we grade it C/D for this condition, ranked here because its direct cartilage record is essentially empty. Pentadeca Arginate (PDA) is a BPC-157 arginate salt analog marketed as a more stable next-generation compound, but it has no PubMed-indexed independent human or animal cartilage or meniscus trial; its reputation is borrowed wholesale from BPC-157's preclinical record, on the unproven assumption that a salt analog behaves identically. We grade PDA D — marketing or mechanistic extrapolation — until independent data exist. Both sit in the same FDA compounding gray zone as the other unapproved peptides, and both carry the same research-chemical purity and identity concerns, with the added uncertainty for PDA that buyers cannot verify what an analog vial actually contains. From an evidence-first standpoint, neither belongs in a serious cartilage or meniscus discussion except as a caution against marketing that outruns data.

Best for

Readers who have seen TB-500 or PDA promoted for joints and want an honest, evidence-first explanation of why they are the weakest-supported options for cartilage and meniscus

Pricing

Not FDA-approved; sold as research chemicals

Source: Thymosin β-4 / TB-500 scoping review, Appl. Sci. 2026;16(12):6202